| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 |
SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 3)*
Werewolf Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
95075A107
(CUSIP Number)
RA Capital Management, L.P.
200 Berkeley Street, 18th Floor
Boston, MA 02116
Telephone: 617.778.2500
Attn: Peter Kolchinsky
(Name, Address and Telephone
Number of Person Authorized to
Receive Notices and Communications)
January 6, 2023
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 282559103 | 13D |
| 1 | Names of Reporting Persons.
RA Capital Management, L.P. | ||
| 2 | Check the Appropriate Box if a Member of a Group (See Instructions) | ||
| (a) ¨ | |||
| (b) ¨ | |||
| 3 | SEC Use Only
| ||
| 4 | Source of Funds (See Instructions):
AF | ||
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e):
¨ | ||
| 6 | Citizenship or Place of Organization.
Delaware | ||
Number of Shares Beneficially Owned by Each Reporting Person With |
7 Sole Voting Power
0 shares | ||
8 Shared Voting Power
6,159,054 shares | |||
9 Sole Dispositive Power
0 shares | |||
10 Shared Dispositive Power
6,159,054 shares | |||
| 11 | Aggregate Amount Beneficially Owned by Each Reporting Person
6,159,054 shares |
||
| 12 | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
¨ |
||
| 13 | Percent of Class Represented by Amount in Row (11)
17.96%1 |
||
| 14 | Type of Reporting Person (See Instructions)
IA, PN |
||
1 The Reporting Person is the beneficial owner of 6,144,881 shares of the Issuer’s Common Stock as well as conversion shares underlying each of 12,883 vested stock options (right to buy) and 1,290 stock options (right to buy) which will vest within 60 days held by Dr. Derek DiRocco for the benefit of RA Capital. The percentage calculation assumes that there are 34,289,494 outstanding shares of Common Stock of the Issuer, based on 34,275,321 outstanding shares of Common Stock of the Issuer based on the Issuer’s Form 8-K filed with Securities and Exchange Commission (“SEC”) on January 10, 2023, and giving effect to stock options referenced above.
| CUSIP No. 282559103 | 13D/A |
| 1 | Names of Reporting Persons.
Peter Kolchinsky | ||
| 2 | Check the Appropriate Box if a Member of a Group (See Instructions) | ||
| (a) ¨ | |||
| (b) ¨ | |||
| 3 | SEC Use Only
| ||
| 4 | Source of Funds (See Instructions):
AF | ||
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e):
¨ | ||
| 6 | Citizenship or Place of Organization.
United States | ||
Number of Shares Beneficially Owned by Each Reporting Person With |
7 Sole Voting Power
0 shares | ||
8 Shared Voting Power
6,159,054 shares | |||
9 Sole Dispositive Power
0 shares | |||
10 Shared Dispositive Power
6,159,054 shares | |||
| 11 | Aggregate Amount Beneficially Owned by Each Reporting Person
6,159,054 shares |
||
| 12 | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
¨ |
||
| 13 | Percent of Class Represented by Amount in Row (11)
17.96%2 |
||
| 14 | Type of Reporting Person (See Instructions)
HC, IN |
||
2 The Reporting Person is the beneficial owner of 6,144,881 shares of the Issuer’s Common Stock as well as conversion shares underlying each of 12,883 vested stock options (right to buy) and 1,290 stock options (right to buy) which will vest within 60 days held by Dr. Derek DiRocco for the benefit of RA Capital. The percentage calculation assumes that there are 34,289,494 outstanding shares of Common Stock of the Issuer, based on 34,275,321 outstanding shares of Common Stock of the Issuer based on the Issuer’s Form 8-K filed with Securities and Exchange Commission (“SEC”) on January 10, 2023, and giving effect to stock options referenced above.
| CUSIP No. 282559103 | 13D/A |
| 1 | Names of Reporting Persons.
Rajeev Shah | ||
| 2 | Check the Appropriate Box if a Member of a Group (See Instructions) | ||
| (a) ¨ | |||
| (b) ¨ | |||
| 3 | SEC Use Only
| ||
| 4 | Source of Funds (See Instructions):
AF | ||
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e):
¨ | ||
| 6 | Citizenship or Place of Organization.
United States | ||
Number of Shares Beneficially Owned by Each Reporting Person With |
7 Sole Voting Power
0 shares | ||
8 Shared Voting Power
6,159,054 shares | |||
9 Sole Dispositive Power
0 shares | |||
10 Shared Dispositive Power
6,159,054 shares | |||
| 11 | Aggregate Amount Beneficially Owned by Each Reporting Person
6,159,054 shares |
||
| 12 | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
¨ |
||
| 13 | Percent of Class Represented by Amount in Row (11)
17.96%3 |
||
| 14 | Type of Reporting Person (See Instructions)
HC, IN |
||
3 The Reporting Person is the beneficial owner of 6,144,881 shares of the Issuer’s Common Stock as well as conversion shares underlying each of 12,883 vested stock options (right to buy) and 1,290 stock options (right to buy) which will vest within 60 days held by Dr. Derek DiRocco for the benefit of RA Capital. The percentage calculation assumes that there are 34,289,494 outstanding shares of Common Stock of the Issuer, based on 34,275,321 outstanding shares of Common Stock of the Issuer based on the Issuer’s Form 8-K filed with Securities and Exchange Commission (“SEC”) on January 10, 2023, and giving effect to stock options referenced above.
| CUSIP No. 282559103 | 13D/A |
| 1 | Names of Reporting Persons.
RA Capital Healthcare Fund, L.P. | ||
| 2 | Check the Appropriate Box if a Member of a Group (See Instructions) | ||
| (a) ¨ | |||
| (b) ¨ | |||
| 3 | SEC Use Only
| ||
| 4 | Source of Funds (See Instructions):
WC | ||
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e):
¨ | ||
| 6 | Citizenship or Place of Organization.
United States | ||
Number of Shares Beneficially Owned by Each Reporting Person With |
7 Sole Voting Power
0 shares | ||
8 Shared Voting Power
5,701,056 shares | |||
9 Sole Dispositive Power
0 shares | |||
10 Shared Dispositive Power
5,701,056 shares | |||
| 11 | Aggregate Amount Beneficially Owned by Each Reporting Person
5,701,056 shares |
||
| 12 | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
¨ |
||
| 13 | Percent of Class Represented by Amount in Row (11)
16.63%4 |
||
| 14 | Type of Reporting Person (See Instructions)
PN |
||
4 The reporting person is the beneficial owner of 5,701,056 shares of the Issuer’s Common Stock. The percentage calculation assumes that there are 34,289,494 outstanding shares of Common Stock of the Issuer, based on 34,275,321 outstanding shares of Common Stock of the Issuer based on the Issuer’s Form 8-K filed with Securities and Exchange Commission (“SEC”) on January 10, 2023, and giving effect to stock options referenced above.
| CUSIP No. 282559103 | 13D/A |
SCHEDULE 13D
Item 1. Security and Issuer
Item 1 of the Statement is hereby amended and supplemented as follows:
This Amendment No. 3 amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission on May 6, 2021 (the “Statement”), as amended by Amendment No. 1 filed on June 16, 2021 and Amendment No. 2 filed on August 12, 2022 by the Reporting Persons with respect to the Common Stock, $0.0001 par value (the “Common Stock”), of Werewolf Therapeutics, Inc. (the “Issuer”). Unless otherwise defined herein, capitalized terms used in this Amendment No. 3 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.
Item 2. Identity and Background
Item 2 of the Statement is hereby amended and restated as follows:
| (a) | This Schedule 13D is being filed on behalf of RA Capital Management, L.P. (“RA Capital”), Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the “Fund”) who are collectively referred to herein as the “Reporting Persons”. |
The Reporting Persons ownership of the Issuer’s securities include (1) 5,701,056 shares of Common Stock held by the Fund, (2) 443,825 shares of Common Stock held by the RA Capital Nexus Fund II, L.P. (the “Nexus Fund II”), (3) a total of 12,883 vested stock options (right to buy), and (4) 1290 stock options (right to buy) which shall vest within 60 days of this filing.
RA Capital Healthcare Fund GP, LLC is the general partner of the Fund and RA Capital Nexus Fund II GP, LLC is the general partner of the Nexus Fund II. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and the Nexus Fund II and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the “Act”), of any securities of the Issuer held by the Fund or the Nexus Fund II. The Fund and the Nexus Fund II have delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s and the Nexus Fund II’s portfolio, including the shares of the Issuer’s Common Stock reported herein. Because the Fund and the Nexus Fund II have divested themselves of voting and investment power over the reported securities they hold and may not revoke that delegation on less than 61 days’ notice, the Fund and the Nexus Fund II disclaim beneficial ownership of the securities they hold for purposes of Section 13(d) of the Act and therefore disclaim any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Statement other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of the Statement shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.
| (b) | The address of the principal business office of each of the Reporting Persons is 200 Berkeley Street, 18th Floor, Boston, MA 02116. |
| CUSIP No. 282559103 | 13D/A |
| (c) | The Fund is a private investment vehicle. RA Capital provides investment management services to the Fund and the Nexus Fund II. The principal occupation of Dr. Kolchinsky and Mr. Shah is investment management. |
| (d) | During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). |
| (e) | During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree of final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. |
| (f) | See Item 6 of the cover pages. |
Item 3. Source and Amount of Funds or Other Consideration
Item 3 of the Statement is hereby amended and supplemented as follows:
The Reporting Persons acquired additional securities of the Issuer in the transactions described in Item 5(c) of this Amendment No. 3 for an aggregate of $4,132,190.00. The securities were purchased through the Issuer’s At-the-Market (“ATM”) facility. The purchase was for cash and was funded by the working capital of the Fund.
Item 4. Purpose of Transaction
Item 4 of the Statement is hereby amended and supplemented as follows:
The Reporting Persons acquired the Common Stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. Although the Reporting Persons currently have no plan or proposal to acquire any additional Issuer securities or to dispose of any of the Issuer securities reported herein, the Reporting Persons may acquire additional Issuer securities from time to time or dispose of Issuer securities they beneficially own, on the open market or in private transactions or otherwise (including by means of 10b5-1 programs), consistent with their investment purposes and in amounts, on such terms and at such times as to be determined by the Reporting Persons based upon a number of factors, including, without limitation, their ongoing assessment of the Issuer’s business prospects, the availability of Issuer securities at prices that would make the purchase or sale of such securities desirable, prevailing market conditions, the availability of other investment opportunities, and/or other considerations.
In addition, consistent with their investment purpose, the Reporting Persons may engage in communications with persons associated with the Issuer, including shareholders of the Issuer, officers of the Issuer, members of the board of directors of the Issuer, and/or or other third parties, to discuss matters regarding the Issuer, including but not limited to its operations, strategic direction, governance or capitalization, and potential business combinations or dispositions involving the Issuer or certain of its businesses. Dr. Derek DiRocco, a Partner of RA Capital, currently serves as a director of the Issuer and therefore will engage in regular discussions with the Issuer’s board of directors and management as part of his duties as a director.
Neither Dr. DiRocco (other than in his capacity as a director) nor the Reporting Persons have any present plans or proposals that relate to, or could result in, any of the matters referred to in paragraphs (a) through (j), inclusive, of the instructions to Item 4 of Schedule 13D.
| CUSIP No. 282559103 | 13D/A |
Depending on various factors including, without limitation, the Issuer’s financial position, results and strategic direction, actions taken by the Issuer’s management and Board, other investment opportunities available to RA Capital, the price levels of the Issuer securities, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may change their purpose and formulate and implement plans or proposals with respect to the Issuer at any time and from time to time. Any such action may be made by the Reporting Persons alone or in conjunction with other shareholders, potential acquirers, financing sources and/or other third parties and could include one or more purposes, plans or proposals that relate to or would result in actions required to be reported herein in accordance with Item 4 of Schedule 13D.
| Item 5. | Interest in Securities of the Issuer |
Item 5 of the Statement is hereby amended and restated as follows:
| (a) | The information set forth in rows 11 and 13 of the cover pages to this Statement is incorporated herein by reference. The percentages set forth in row 13 of the cover pages are based on 34,275,321 outstanding Ordinary Shares of the Issuer as reported in the Issuer’s Form 8-K filed with the Securities and Exchange Commission (“SEC”) on January 10, 2023. |
| (b) | The information set forth in rows 7 through 10 of the cover pages to this Statement and Item 2 above is incorporated herein by reference. |
| (c) | The following table lists the Reporting Persons’ transactions in Common Stock that were effected during the sixty day period prior to the filing of this Schedule 13D: |
| Transaction | Purchaser | Date | No. Shares | Price | ||||||||
| ATM Purchase | The Fund | 06-Jan-2023 | 1,853,000 | $ | 2.21 | |||||||
| Vest Stock Option (Right to Buy) | RA Capital | 11-Nov-2022 | 645 | (1) | ||||||||
| Vest Stock Option (Right to Buy) | RA Capital | 11-Dec-2022 | 645 | (1) | ||||||||
| Vest Stock Option (Right to Buy) | RA Capital | 9-Feb-2023 | 645 | (1)* | ||||||||
| Vest Stock Option (Right to Buy) | RA Capital | 11-Mar-2023 | 645 | (1)* | ||||||||
| (d) | No person (other than the Reporting Persons) is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock subject to this Statement. |
| (1) | This option represents a right to purchase a total of 23,200 shares of the Issuer's Common Stock, one third of which vested on April 30, 2022, with the remaining two thirds vesting in equal monthly installments over the following two years, subject to Dr. DiRocco’s continued service to the Issuer through each vesting date. These options have an exercise price of $16.00. |
| * | Represents future vesting within 60 days from the filing date of this Form 13D/A. |
| CUSIP No. 282559103 | 13D/A |
Item 7. Material to Be Filed as Exhibits
Exhibit 1 Joint Filing Agreement
| CUSIP No. 282559103 | 13D/A |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: January 10, 2023
RA CAPITAL MANAGEMENT, L.P.
| By: | /s/ Peter Kolchinsky | ||
| Name: | Peter Kolchinsky | ||
| Title: | Authorized Signatory | ||
PETER KOLCHINSKY
| /s/ Peter Kolchinsky |
RAJEEV SHAH
| /s/ Rajeev Shah |
RA CAPITAL HEALTHCARE FUND, L.P.
| By: | RA Capital Healthcare Fund GP, LLC |
| Its: | General Partner |
| By: | /s/ Peter Kolchinsky | ||
| Name: | Peter Kolchinsky | ||
| Title: | Manager | ||
| CUSIP No. 282559103 | 13D/A |
EXHIBIT 1
JOINT FILING AGREEMENT
This Joint Filing Agreement, dated as of January 10, 2023, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”).
Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G and/or 13D with respect to Common Stock, par value $0.0001 per share of Werewolf Therapeutics, Inc. beneficially owned by them from time to time.
Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.
This Joint Filing Agreement may be terminated by any of the Filers upon one week’s prior written notice or such lesser period of notice as the Filers may mutually agree.
Executed and delivered as of the date first above written.
RA CAPITAL MANAGEMENT, L.P.
| By: | /s/ Peter Kolchinsky | ||
| Name: | Peter Kolchinsky | ||
| Title: | Authorized Signatory | ||
PETER KOLCHINSKY
| /s/ Peter Kolchinsky |
RAJEEV SHAH
| /s/ Rajeev Shah |
RA CAPITAL HEALTHCARE FUND, L.P.
| By: | RA Capital Healthcare Fund GP, LLC |
| Its: | General Partner |
| By: | /s/ Peter Kolchinsky | ||
| Name: | Peter Kolchinsky | ||
| Title: | Manager | ||